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Abstract
High numbers of Toxoplasma gondii oocysts in the environment are a risk factor to humans. The environmental
contamination might be reduced by vaccinating the definitive host, cats. An experimental challenge model is necessary to
quantitatively assess the efficacy of a vaccine or drug treatment. Previous studies have indicated that bradyzoites are highly
infectious for cats. To infect cats, tissue cysts were isolated from the brains of mice infected with oocysts of T. gondii M4
strain, and bradyzoites were released by pepsin digestion. Free bradyzoites were counted and graded doses (1000, 100, 50,
10), and 250 intact tissue cysts were inoculated orally into three cats each. Oocysts shed by these five groups of cats were
collected from faeces by flotation techniques, counted microscopically and estimated by real time PCR. Additionally, the
number of T. gondii in heart, tongue and brains were estimated, and serology for anti T. gondii antibodies was performed. A
Beta-Poisson dose-response model was used to estimate the infectivity of single bradyzoites and linear regression was used
to determine the relation between inoculated dose and numbers of oocyst shed. We found that real time PCR was more
sensitive than microscopic detection of oocysts, and oocysts were detected by PCR in faeces of cats fed 10 bradyzoites but
by microscopic examination. Real time PCR may only detect fragments of T. gondii DNA without the presence of oocysts in
low doses. Prevalence of tissue cysts of T. gondii in tongue, heart and brains, and anti T. gondii antibody concentrations were
all found to depend on the inoculated bradyzoite dose. The combination of the experimental challenge model and the dose
response analysis provides a suitable reference for quantifying the potential reduction in human health risk due to a
treatment of domestic cats by vaccination or by therapeutic drug application.
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Introduction
Toxoplasmosis, caused by the protozoan parasite Toxoplasma
gondii has a worldwide distribution, one-third of the global human
population has been exposed to this parasite [1]. The integrated
public health impact defined as disease burden expressed in
Disability Adjusted Life Years (DALYs) is globally considered to be
very high [2]. In the USA, T. gondii ranked third out of 14
foodborne pathogens [3] and in the Netherlands, the total burden
of toxoplasmosis was estimated 3620 DALYs, ranking T. gondii as
the first among 14 enteral pathogens examined [4]. Because of this
high public health impact of toxoplasmosis intervention measures
need to be implemented.
Cats and other Felidae are the primary source of a T. gondii
infection [5,6]. Cats become infected by feeding on infected meat
(wild rodents and birds) or, less effectively, by ingestion of
sporulated oocysts [7]. This results in an, for cats only
enteroepithelial sexual cycle that leads to the shedding of millions
of oocysts into the environment within a period of two to three
weeks [8,9,10,11]. The oocysts may contaminate the environment
and can resist extreme environmental conditions, remaining
infectious for periods up to 18 months [12] or longer [13,14].
Toxoplasma may be transmitted to humans through the
consumption of raw or undercooked meat from livestock (e.g.
pigs, cows and sheep) containing tissue cysts [15] or by ingesting of
food or water contaminated with oocysts from infected cat faeces
[16,17]. T gondii can also be transmitted vertically by a primary
infection with T. gondii during pregnancy and entering of the
parasite into the foetal circulation by infection of the placenta [18].
Since T. gondii can be considered a major foodborne pathogen,
the development of strategies to prevent humans to become
infected is of increasing importance. The ultimate control strategy
would be to prevent infected cats from shedding oocysts in the
environment. Although vaccines nor other drug treatments in cats
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are yet commercially available, such control strategies may
become available in the future [19,20,21].
To evaluate the efficacy of vaccines or drugs, a standardised
animal model is needed. Cats can be experimentally infected with
tissue cysts [22] whereby only a few tissue cysts are necessary to
infect cats [23]. Isolated bradyzoites from tissue cysts are also very
infectious for cats [25,26,27], after ingesting a few bradyzoites cats
can shed millions of oocysts [25].
Several studies have been published studying T. gondii vaccine
development in cats [28,29,30,31,32,33,34]. In these studies,
vaccines were evaluated using 200 to1000 brain tissue cysts
produced in mice to challenge orally cats. However, a tissue cyst
may contain 2 to 1,000 bradyzoites [24] indicating that the dose is
not well defined when tissue cysts are used to infect cats.
It was our aim to develop a standardised challenge model in
cats. Cats were experimentally infected with various doses of
bradyzoites harvested from tissue cysts of experimentally infected
mice. The results were used to estimate the infectivity, by means of
a dose response model, appropriate for challenge studies in cats.
We found that shedding of oocysts by cats after experimental
infection is dose- and time-dependent.
Materials and Methods
2.1. Toxoplasma strain
Oocysts from T. gondii genotype II strain M4 were obtained
from Prof. Dr. E.A. Innes of the Moredun Research Institute
(Edinburgh, Scotland).
2.2 T. gondii infection in mice: preparing of inoculum for
infection of cats
To prepare tissue cysts and bradyzoites for experimentally
infecting cats, Swiss Webster mice at the age of six weeks were
orally infected with 100 oocysts of T. gondii M4 strain in a volume
of 0.25 ml PBS. At seven weeks p.i. three mice were sacrificed,
brains were collected and brain tissue cysts were harvested by a
discontinuous 30–90% Percoll gradient [35] according to the
modified protocol of Fritz et al. [27]. Briefly, three-quarters of
each brain were passed through a 100 mm cell strainer into a
50 ml conical tube. The plunger of a six ml syringe was used to
press the brain tissue through the strainer, thereby retaining the
fatty tissue in the strainer. Brain tissue was washed with PBS and
resuspended in a volume of 4 ml. A density gradient was prepared
for each sample in a 50 ml conical tube by carefully layering (from
bottom to top) 9 ml 90% Percoll, followed by 9 ml 30% Percoll
and finally followed by 10 ml brain suspension. Percoll dilutions
were made using one6PBS. Gradient preparations were centri-
fuged at 12006 g for 15 min at 4uC. Tissue cysts were harvested
from the 30% and 30%/90% interface, suspended in 45 ml PBS
and centrifuged at 30006 g for 15 min at 4uC. The supernatant
was removed and the pellet containing the tissue cysts was
transferred to a 1.5 ml micro centrifuge tube. The volume was
brought up to one ml with Hank’s Balanced Salt Solution (HBSS;
Life Technologies Europe BV Bleiswijk, the Netherlands). A 25 ml
aliquot was used for tissue cyst enumeration under light
microscopy at a 406 magnification. To release the bradyzoites
from the tissue cysts an equal volume of pepsin digestive fluid
(0.26 g pepsin; 5 g NaCl; 7 g HCl; distilled water to 500 ml) was
added to the tissue cysts (final concentration 0.026%) [36].
Subsequently, the suspension was incubated at 37uC for 10 min,
neutralized with Na2CO3 and suspended in Dulbecco’s modified
Eagle’s medium (DMEM) plus 3% foetal calf serum (FCS).
Bradyzoites were counted in a haemocytometer and adjusted to a
concentration of 2.56103/ml.
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To prepare bradyzoites and tissue cysts for infection of cats, ten
mice were orally inoculated with 100 oocysts of T. gondii strain
M4. At seven weeks p.i. three mice were sacrificed. Per mouse
brain 80–1200 tissue cysts were collected and per tissue cyst 166–
275 bradyzoites were collected. To infect cats with bradyzoites, a
stock solution of 2.5 * 103 bradyzoites per ml was prepared and
further diluted preparing inoculation doses of 1000, 100, 50, and
10 bradyzoites in a volume of 2.5 ml. To infect cats with tissue
cysts a solution of 250 tissue cysts in a volume of 2.5 ml was
prepared.
2.3 T. gondii infection in cats
Fifteen cats (10 male and 5 female) at the age of 11 weeks were
obtained from Isoquimen, Sant Feliu de Codines, Spain. In a
health monitoring report, the supplier of the cats declared that the
cat colony is free for T. gondii as determined by blood serum
testing for anti T. gondii antibodies and examination of faeces for
the presence of oocysts. For verification of absence of T. gondii
infection, blood serum of the mothers (n = 8) of the kittens was
obtained in advance of delivery of the kittens and tested for anti T.
gondii antibodies by an indirect ELISA with tachyzoite antigen as
described below. After transport to the animal facilities of CVI
(Lelystad, The Netherlands), the kittens received commercially
available dry food and tap water ad libitum. Kittens were housed
individually in an accommodation according to EU regulation
2007/526/EC. General health observations were conducted daily
during cleaning and feeding activities and during social interaction
with biotechnicians. Kittens were acclimatized to the animal
experimental facility for seven days. During the acclimatization
period, oocysts counts were performed in faeces as described
below to demonstrate the absence of a T. gondii infection. At the
age of 12 weeks, five groups of three kittens were orally challenged
with 1000, 100, 50 and 10 bradyzoites of the T. gondii M4 strain
in 2.5 ml DMEM-3% FCS using a curved blunt cannula. One
group of three SPF kittens was orally challenged with 250 brain
tissue cysts from mice infected with T. gondii M4 strain in 2.5 ml
PBS. Between 3 and 21 days after inoculation, all faeces were
collected daily from a litter box filled with grit. From each kitten,
all faeces was sieved out, collected and sent to the laboratory. The
litter box was cleaned thereafter.
From each kitten, faeces was weighed and oocysts were purified
from 2 gram out of 25 gram mixed faeces by 100 mM sieving, and
saturated NaCl (d= 1.18 g/ml) flotation according to Wainwright
et al. [37]. Oocysts were floated by centrifugation at 2500 g for
10 minutes (non-braked). A sample of 200 ml with floated oocysts
was taken by carefully pipetting from the uppermost part of the
contents of the centrifuge tube. In this sample the number of
floated oocysts per gram (OPG) was counted using a haemocy-
tometer and the quantity of T. gondii DNA was determined by
real time PCR for 529 T. gondii gen as described below.
Determination of oocyst shedding was finished when no oocysts
had been detected for three consecutive days. Serum samples were
collected from a jugular vein of the kittens at the day of challenge
and at one, two, and three weeks post-challenge (p.c.). At three
weeks post challenge, when no more shedding occurred the
experiment was terminated. Kittens were brought under full
narcosis with 40 mg/kg Ketamine (Alfasan, Woerden, The
Netherlands) plus 2 mg/kg Xylazine (Eurovet, Putten, The
Netherlands) and 0.05 mg/kg Atropine (Eurovet, Putten, The
Netherlands). Subsequently, kittens were bled and from each
kitten, samples were obtained from brains, tongue and heart for
detection of T. gondii. A quarter of the brains of each kitten was
passed through a 100 mm cell strainer into a 50 ml conical tube
using the plunger of a six ml syringe to press the tissue through the
strainer (retaining the fatty tissue in the strainer) and washed with
PBS to a total volume of four ml. Three-quarters of the tongue and
heart of each kitten were homogenized in four ml PBS with a
disposable Omni Tissue homogenizer during one minute. A 25 ml
aliquot was taken for cyst determination under light microscopy at
a magnification of 406 and an aliquot of 200 ml was taken for
DNA extraction.
2.4 DNA extraction and real time PCR conditions
For detection of T. gondii by real time PCR, 200 ml floated
oocysts preparations from faeces of cats, heart, brain and/or
tongue tissue samples of kittens were further homogenized by
vortexing the samples with 50–100 glass beads (0.4 mm) for one to
two minutes. Microscopically it was confirmed that after this
treatment most oocysts and tissue cysts had been broken. DNA
was extracted with the Qiagen DNA easy Blood & Tissue Kit
(Qiagen GMBH, Hilden, Germany) according to the manufac-
turer’s manual. One ml DNA was tested by the PCR with on-line
detection using Syber Green PCR Master Mix (Applied Biosys-
tems, Foster City, CA, USA) in an ABI 7500 Real-Time PCR
system (PE Applied Biosystems, Foster City, CA, USA). A
standard reaction mixture contained 12.5 ml of two6QuantiTect
SYBR Green PCR Master Mix, one ml (10 mM) of the primers,
one ml of DNA template and 10.5 ml PCR grade water. The Tox-
oligonucleotides are complementary to the 529-bp repeat element
(GenBank AF146527) [38] and the forward and reverse Toxo-
plasma primers were described previously as Tox-9, and Tox-11
[39]. The cycling profile involved an initial PCR activation step at
95uC for 10 min, followed by 40 cycles of denaturation at 94uC for
15 s, primer annealing at 59uC for 30 s and extension at 72uC for
30 s. The fluorescence was measured at the end of each cycle.
Following amplification, a melt curve analysis was performed to
verify the specificity of the amplified products by their specific
melting temperatures (Tm). Post amplification melting curve with
SYBR Green dye of Toxoplasma positive DNA samples revealed
one peak. For quantification of the amount of Toxoplasma DNA
in the samples, a standard curve of a plasmid containing the 529
repeat gen in pGEM-T easy (Promega Benelux b.v. Leiden, The
Netherlands) was used. Amounts of DNA were based on the log 10
dilutions of the standard. All samples analysed had a blank PCR
control and samples negative for Toxoplasma DNA are depicted
in Fig. 1B as 40-Ct = 0, whereas samples with 40-Ct.0 were
considered as positive. Data acquisition and analysis of the results
were performed using the 7500 System SDS Software Version
2.0.1 (Applied Biosystems).
2.5 Serology for T. gondii
Serum samples of the infected cats were processed with an in-
house developed ELISA test for determining anti T. gondii
antibody titers. ELISA plates (Nunc Polysorp 475094; Sanbio,
Uden, The Netherlands) were coated with a T. gondii tachyzoites
lysate (5 mg/ml in Na2CO3 buffer pH 9.5) overnight at 37uC.
Wells were incubated for one h at 37uC with sera in two-fold
dilutions from 1/25 to 1/3200 in PBS containing 0.05% Tween-
Figure 1. Oocysts shedding (A), real time PCR values of the oocysts shedding (B) and antibody response (log2 titres) (C) from the
kittens infected with 10, 50, 100 and 1000 bradyzoites or 250 tissue cysts of T. gondii Strain M4. The groups contained three cats each.
*P,0.05 significant to the anti T. gondii IgG response at week 0.
doi:10.1371/journal.pone.0104740.g001
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80. The next incubation was for one h at 37uC with a peroxidase-
conjugated Goat anti Cat-h&l (clone 10MG1-2, Bio connect,
Huisen, The Netherlands) HRPO conjugate in a dilution of
1:10.000 in ELISA buffer. Serum from cats either infected or free
from a T. gondii infection were used as positive and negative
control. As substrate, 3,39,5,59-tetramethylbenzidine (TMB) with
H2O2 was used. After incubation for 5 min at room temperature,
the reaction was stopped by the addition of sulphuric acid. The
plate was read by the use of a Bio-Kinetics ELISA reader (Bio-Tek
Instruments Inc., Winooski, VT) at 450 nm. Antibody titres were
expressed as the 2-log of the regression coefficient of the optical
density vs. serum concentration. Per group of three cats, ELISA
results were taken to calculate the geometric means and standard
deviations. Antibody titres (2-log) were compared to antibody titre
in serum samples at day 0, and were analysed for statistical
significance by the Mann-Whitney U test in the GraphPad Prism
version 5.0 software, and where considered significant if the P-
value,0.05.
2.6 Dose-Response Model
The infection status of cats inoculated with T. gondii M4, as
judged by OPG count .0 was fitted by a Beta-Poisson dose-
response model [40]. This model is based on the assumption that
any single viable bradyzoite may cause infection, and accounts for
variability in the probability of infection resulting from variation in
host susceptibility or pathogen infectivity, due to genetic or other
factors. Sampling effects in the applied inoculum were accounted
for by assuming that the ingested number of bradyzoites is a
Poisson sample from a suspension with mean equal to the target
dose. Given a certain probability of infection at each dose, the
numbers of infected cats at that dose are binomially distributed.
Using the binomial likelihood the two parameters (a, b) can be
estimated. A Monte Carlo sample of dose response parameters was
obtained based on the oocysts output using JAGS (3.2.0), a
program for analysis of Bayesian hierarchical models using
Markov chain Monte Carlo (MCMC) analysis (http://mcmc-
jags.sourceforge.net).
2.7 Animal Ethics Committee
The animal study has been conducted with permission of the
Animal Ethics Committee of the Animal Sciences Group
(Lelystad, the Netherlands) dated 3 October 2012, registered
under number 2012073.c.
3. Results
3.1 T. gondii infection in kittens
None of the cats showed any clinical symptom (depression,
central nervous behaviour, gastro intestinal signs, diarrhoea)
throughout the study period.
Oocysts in faeces. The dynamics of oocyst shedding by cats
after challenge infection with mouse bradyzoites or tissue cysts of
T. gondii strain M4 is shown in Table 1. All three kittens from the
group infected with 250 tissue cysts shed oocysts in the faeces from
day 4 till day 16 (Fig. 1A). The three kittens infected with 1000
bradyzoites shed oocysts from day 6 till day 17. At peak shedding
on day 6–7 p.i, the kittens in this group produced 5* 10‘6 oocysts
per gram faeces (OPG). From the kittens infected with 100 or 50
bradyzoites only one out of three shed oocysts at day 7–16 p.i., and
from the kittens infected with 10 bradyzoites none shed oocysts, as
determined microscopically.
Real time PCR of faeces. All kittens which tested positive by
microscopic examination were also positive by real time PCR.
Moreover, all OPG-negative animals: the two negative kittens
infected with 50 or 100 bradyzoites, and all kittens challenged with
10 bradyzoites became also positive for T. gondii by real rime
PCR (Fig. 1B). The Ct values in these lower dose groups were
higher showing that the concentration of available DNA was
lower.
Serology. Compared to kittens in the other groups, the
kittens that were infected with 250 tissue cysts or 1000 bradyzoites
Table 2. Prevalence of tissue cysts as revealed by real time PCR of the heart, tongue and brains of cats infected with bradyzoites or
tissue cysts of T. gondii strain M4.
Kitten no. Dose Infectious Material 40-Ct value
Heart Tongue Brains
7581 10 Bradyzoites 0 0 0
7582 10 Bradyzoites 0 0 0
7583 10 Bradyzoites 0 0 0
7578 50 Bradyzoites 0 0 0
7579 50 Bradyzoites 9.0 13.4 0
7580 50 Bradyzoites 0.2 0.0 0
7575 100 Bradyzoites 0 0.0 0
7576 100 Bradyzoites 0 0.0 4.1
7577 100 Bradyzoites 5 11.7 0
7572 1000 Bradyzoites 0 12.8 0
7573 1000 Bradyzoites 11.6 14.4 0
7574 1000 Bradyzoites 12.2 15.5 0
7584 250 Tissue cysts 3.2 0 0
7585 250 Tissue cysts 0 0 0
7586 250 Tissue cysts 11.7 0 0
doi:10.1371/journal.pone.0104740.t002
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had the highest titres (Fig. 1C). In both groups, antibody titres at
14 and 21 days p.c. appeared to be significantly higher (P,0.05)
compared to day 0. In the other dose groups the increase was
much smaller and in the kittens infected with 10 or 50 bradyzoites
we found a significant increase in IgG titre (P,0.05) respectively
at week three and two compared to antibody titre in serum
samples obtained at day 0. One kitten (nr 7579) of the group
infected with 50 bradyzoites showed an IgG titre of 5.7 (2log) at
day 21 p.c., shedding of oocysts in faeces of this cat was only
confirmed by real time PCR and not microscopically.
Real Time PCR and microscopy of brain, tongue and
heart. The real time PCR results detected T. gondii DNA in
five tongue and in seven heart samples of the infected kittens. Of
all the brain samples tested, only one kitten (100 bradyzoites) had
very low Ct values in the real time PCR on brain samples, the
other 14 kittens were negative (Table 2). Ct values after PCR
testing of heart and tongue of the cats infected with 1000
bradyzoites were comparable, indicating that there was no
difference in distribution of tissue cysts over the tongue, and
heart. (Table 2). Microscopically, we did not find any tissue cysts
in brain, heart and tongue samples.
3.2 T. gondii dose response model in cats
Infection was defined as: 1. counting one or more oocysts in
faecal samples (oocysts per gram, OPG), and 2. positive results of
the real time PCR of faecal samples. The estimated mean ID50
based on the OPG counts is 181 bradyzoites (36–806 bradyzoites,
95% credible interval (ci), Fig. 2A). The estimated probability of
infection per single bradyzoite is 0.02 (95% ci 0.003–0.13 per
single bradyzoites, Fig. 2B). Based on the infection as determined
by real time PCR, the estimated mean ID50 is two bradyzoites
with a 95% credible interval of 0.044–11 bradyzoites. Equiva-
lently, the probability of infection per single bradyzoite is 0.38
(95% ci 0.08–0.52 per single bradyzoite). To investigate whether
infectivity is specific to the M4-strain, we also applied this dose
response model to a similar experimental challenge model in
Figure 2. Panels in column A illustrate the dose-response for Toxoplasma gondii in cats: Horizontal axes show mean number of
bradyzoites; vertical axes show probability that a cat is infected following ingestion. Each panel refers to: OPG of M4 strain (top), real
time-values of M4 strain (middle) and OPG of VEG strain (bottom). Panels in column B illustrate posterior density for the dose response parameter
(probability of infection by a single bradyzoites): Horizontal axes show possible estimate for the parameter; vertical axes show probability density.
Solid line indicates the mean and dashed lines are 2.5% and 97.5% percentiles.
doi:10.1371/journal.pone.0104740.g002
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which the VEG strain was used (Fig. 2C; the datasets of
experiment I and II from Dubey [25]). Using OPG.0 to
characterize infection, the estimated mean ID50 was 214
bradyzoites (95% ci 7–1800 bradyzoites). To investigate whether
the estimated infectivities of the M4 and VEG strains (Fig. 2A; M4
and VEG OPG) are different, a likelihood ratio test was done,
showing that a model assuming equal infectivities of M4 and VEG
did not provide a significantly worse fit than the two separate
infectivity estimates (P-value = 0.47: likelihood ratio test, 2 d.f.).
The total OPG and DNA count shed by cats in the experimental
groups using 10, 100 and 1000 bradyzoiets are shown in Fig. 3A
and B. In addition, the total OPG counts shed by cats in the
experimental infections as described by Dubey [25] are shown in
Fig. 3C indicating that total OPG shedding was indeed in the
same order of magnitude for the two studies.
Discussion
The aim of our study was to establish a standardised challenge
model in cats as a reference for studying the effectiveness of
vaccines or therapeutic drugs against T. gondii infection in cats.
We selected T. gondii strain M4. This strain belongs to
genotype II, the most predominant T. gondii genotype in Europe
[41]. Strain M4 is able to produce brain tissue cysts in mouse and
oocysts in the gut of cats [27]. Strain M4 is therefore a suitable
candidate for a standardised challenge model in cats.
To prepare the challenge inoculum to experimentally infect
cats, a sufficiently concentrated suspension of fresh bradyzoites
and tissue cysts was produced in mice, seven weeks after oral
infection with oocysts. This finding is in agreement with other
studies [22] in which harvesting tissue cysts after 6–8 weeks is
sufficient time for infectious stages to develop.
We inoculated cats at an age of 12 weeks orally with four
different doses (from low to high) of bradyzoites and determined a
dose-response model for T. gondii. None of the challenged cats
had clinical symptoms. This is in agreement with previous findings
that cats older than three months rarely develop clinical signs after
oral infection with tissue cysts [22].
We found that cats can shed millions of oocysts in their faeces
after ingesting as few as 50 bradyzoites. These results are in
agreement with results obtained by Dubey [25] who found that
100 bradyzoites of T. gondii strain VEG orally inoculated could
lead to shedding of oocysts in the faeces. Our findings confirm the
high infectivity of the bradyzoite stage of the parasite for cats
[25,26,27]; therefore this parasite stage is an important candidate
for use as challenge inoculum in vaccination or treatment-
challenge studies in cats. Other authors [26,29,32,34] used mouse
tissue cysts to infect cats, however as found by others and
confirmed in this study, tissue cysts may contain five to several
hundreds of bradyzoites, ‘‘depending on the age of the cysts’’ [24].
Suspended bradyzoites in contrast to tissue cysts provide a
reproducible dose. Using the different T. gondii strain M4
bradyzoites doses in cats, we found a dose response relation. In
addition, there was no significant difference in the dose response
between the T. gondii M4 strain used in this study and the T.
gondii VEG strain as reported by Dubey [25] using OPG as a
response. Concerning M4 strain only, a dose response relation
shifted toward higher infectivity when real time PCR positivity
instead of OPG is chosen as an endpoint. Real time PCR and
microscopy both detect oocyst shedding, but the 529 repeat
element detected by real time PCR is present in 200–300 copies
per parasite and is therefore more sensitive [38]. At low doses (100
– 50 bradyzoites), real time PCR detects more positives, and even
in the lowest dose group (10 bradyzoites) the real time PCR detects
low levels of shedding of T. gondii genomes. Interestingly, these
low dose shedding responses appear different from those in OPG
positive animals. The Ct values are 10–15 cycles lower than those
in OPG positive, and the duration of shedding is 5–10 days
shorter. The question is whether this low-level shedding represents
true infection, producing infectious oocysts. The real time PCR
assay may detect the DNA extracted from infectious oocysts in all
dose groups (as confirmed with OPG shedding) or it may only
detect fragments of T. gondii DNA without the presence of oocysts
in low dose groups. This might have consequences in case of
Figure 3. Total amount of T. gondii shedding per individual
infected cat: M4 strain based on the OPG faecal output (A), the
real time PCR DNA values in the faeces (B), the VEG strain (C)
based on the OPG faecal output.
doi:10.1371/journal.pone.0104740.g003
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challenge studies to evaluate the vaccine effectiveness for example,
since only infectious oocysts shed by cats are a risk for humans and
are thus of epidemiological relevance.
In previous studies, it was described that pre-patent periods in
cats differs from 3 to10 days after the ingestion of tissue cysts
(bradyzoites) and 18 days or more after the ingestion of oocysts or
tachyzoites [23,42,43,44]. Our study confirmed that the prepatent
period was 5–7 days among all bradyzoite challenge doses. The
patent period increased with the increasing dose of bradyzoites.
Hence, it is an important feature to determine the optimal dose for
vaccination challenge or therapy experiments.
It has been described that IgG antibodies are initially absent
during primary T. gondii infection in cats, but then start to
increase after a few weeks to reach protective levels and then
remain detectable for years. IgM antibodies rise within days, and
usually decrease over the following few weeks. Dubey et al. [45]
reports that cats seroconverted 10 days p.i and high titres persisted
even after 6 years, however, in some cats with a chronic infection
IgM persists. In the present study we detected significantly higher
IgG titres as early as three weeks after infection in cats that
received the highest dose of T. gondii bradyzoites and the tissue
cysts challenge group.
We detected T. gondii DNA by real time PCR in tongue, heart
and in one brain tissue of infected cats. Dubey described earlier
the detection of T. gondii tissue cysts in heart, skeletal muscles,
diaphragm, brain, spleen, kidneys; pancreas, stomach, adrenals,
lungs, thymus, cervical and mesenteric lymph nodes salivary
glands and eyes and tongue of bradyzoites infected cats [26], of
which tongue, heart and brain were important target organs
[46].The cats with the highest infection dose revealed a high T.
gondii DNA load in tongue and heart.
In summary, we conclude that the oocysts of T. gondii strain
M4 can be used to produce high numbers of bradyzoites in the
brain of the mouse to be used as a challenge model in cats.
Moreover, the bradyzoite stage of T. gondii strains can be used to
establish a dose response model for oral challenge with T. gondii in
the cat. The dose response in cats is T. gondii strain independent
at least for the M4 and VEG strains. However, the results using
microscopy or real time PCR will have influence on the outcomes
of the dose response, most likely caused by differences in detection
limit of each assay. Both the probability of infection and the
numbers of oocysts shedded by infected cats appeared to depend
on the challenge dose. Therefore, we can use this M4 challenge
model quantitatively to determine the effects of any intervention,
vaccine or drug induced, expressed in a reduction of the total
oocyst output of T. gondii clonal types II and III infected cats. For
the future, our T. gondii dose response model in cats can be
exploited to evaluate different strategies aiming at cats to reduce
oocysts shedding.
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